Kodiak Sciences Inc (KOD)

Currency in USD
25.860
-2.180(-7.77%)
Closed·
25.750-0.110(-0.43%)
·
KOD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.60028.780
52 wk Range
1.92031.180
Key Statistics
Prev. Close
28.04
Open
28.33
Day's Range
25.6-28.78
52 wk Range
1.92-31.18
Volume
526.56K
Average Volume (3m)
858.62K
1-Year Change
222.8464%
Book Value / Share
0.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KOD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.000
Upside
+12.14%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Kodiak Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Kodiak Sciences Inc Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc SWOT Analysis


Pipeline Promise
Explore Kodiaq Sciences' diverse eye disease treatment portfolio, including KSI-101, tarcocimab, and KSI-501, with key trial results expected in 2025-2026
Financial Hurdles
Delve into the company's financial challenges, with negative EPS forecasts and a declining stock price, balanced against its cash-rich balance sheet
Market Positioning
Learn how Kodiaq Sciences aims to differentiate itself in the competitive biotech sector through innovative treatments and a new wearable OCT device
Future Outlook
Analyst price targets range from $3 to $4, reflecting cautious optimism amid clinical trial uncertainties and potential market opportunities
Read full SWOT analysis

Compare KOD to Peers and Sector

Metrics to compare
KOD
Peers
Sector
Relationship
P/E Ratio
−7.4x−4.2x−0.6x
PEG Ratio
0.570.130.00
Price/Book
67.6x6.0x2.6x
Price / LTM Sales
-65.5x3.4x
Upside (Analyst Target)
35.3%98.4%41.5%
Fair Value Upside
Unlock−8.5%4.4%Unlock

Analyst Ratings

6 Buy
2 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 29.000
(+12.14% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy38.00+46.95%26.00MaintainJan 22, 2026
UBS
Buy50.00+93.35%-New CoverageJan 07, 2026
H.C. Wainwright
Buy26.00+0.54%24.00MaintainNov 17, 2025
H.C. Wainwright
Buy24.00-7.19%5.00UpgradeNov 11, 2025
JPMorgan
Buy24.00-7.19%15.00UpgradeOct 24, 2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-1.16 / -1.02
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KOD Income Statement

People Also Watch

473.83
SNDK
-5.88%
12.170
ONDS
-3.57%
211.88
ONTO
+0.04%
29.36
TDC
-1.84%
6.45
IBRX
-12.13%

FAQ

What Is the Kodiak Sciences (KOD) Stock Price Today?

The Kodiak Sciences stock price today is 25.860

What Stock Exchange Does Kodiak Sciences Trade On?

Kodiak Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Kodiak Sciences?

The stock symbol for Kodiak Sciences is "KOD."

What Is the Kodiak Sciences Market Cap?

As of today, Kodiak Sciences market cap is 1.60B.

What Is Kodiak Sciences's Earnings Per Share (TTM)?

The Kodiak Sciences EPS (TTM) is -4.12.

When Is the Next Kodiak Sciences Earnings Date?

Kodiak Sciences will release its next earnings report on Mar 25, 2026.

From a Technical Analysis Perspective, Is KOD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Kodiak Sciences Stock Split?

Kodiak Sciences has split 0 times.

How Many Employees Does Kodiak Sciences Have?

Kodiak Sciences has 123 employees.

What is the current trading status of Kodiak Sciences (KOD)?

As of Jan 25, 2026, Kodiak Sciences (KOD) is trading at a price of 25.860, with a previous close of 28.040. The stock has fluctuated within a day range of 25.600 to 28.780, while its 52-week range spans from 1.920 to 31.180.

What Is Kodiak Sciences (KOD) Price Target According to Analysts?

The average 12-month price target for Kodiak Sciences is USD29.000, with a high estimate of USD50 and a low estimate of USD2. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +12.14% Upside potential.

What Is the KOD Premarket Price?

KOD's last pre-market stock price is 28.000. The pre-market share volume is 3,790.000, and the stock has decreased by -0.040, or -0.140%.

What Is the KOD After Hours Price?

KOD's last after hours stock price is 25.750, the stock has decreased by -0.110, or -0.430%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.